These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 22343966)
1. A new era for castrate resistant prostate cancer: a treatment review and update. Fong MK; Hare R; Jarkowski A J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966 [TBL] [Abstract][Full Text] [Related]
2. New treatment options for castrate-resistant prostate cancer: a urology perspective. Gomella LG; Gelpi F; Kelly WK Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708 [TBL] [Abstract][Full Text] [Related]
3. New agents in the arsenal to fight castrate-resistant prostate cancer. Ezzell EE; Chang KS; George BJ Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553 [TBL] [Abstract][Full Text] [Related]
4. New treatment options for castration-resistant prostate cancer. Simondsen K; Kolesar J Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346 [TBL] [Abstract][Full Text] [Related]
6. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545 [TBL] [Abstract][Full Text] [Related]
7. Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint. Birtle A Expert Rev Anticancer Ther; 2013 Jan; 13(1):89-99. PubMed ID: 23259430 [TBL] [Abstract][Full Text] [Related]
8. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. D'Amico AV J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221 [No Abstract] [Full Text] [Related]
9. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Pal SK; Sartor O Maturitas; 2011 Feb; 68(2):103-5. PubMed ID: 21093995 [TBL] [Abstract][Full Text] [Related]
10. The role of abiraterone in the management of metastatic castration-resistant prostate cancer. Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680 [TBL] [Abstract][Full Text] [Related]
11. Management of docetaxel failures in metastatic castrate-resistant prostate cancer. Pal SK; Lewis B; Sartor O Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533 [TBL] [Abstract][Full Text] [Related]
12. New agents for the management of castration-resistant prostate cancer. Cersosimo RJ Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351 [TBL] [Abstract][Full Text] [Related]
13. New prostate cancer drugs hold promise. Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897 [No Abstract] [Full Text] [Related]
14. New treatment options for patients with metastatic castration-resistant prostate cancer. Higano CS Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872 [TBL] [Abstract][Full Text] [Related]